Drug delivery compositions and methods

• US 4,963,367 A
• Filed: 12/15/1987
• Issued: 10/16/1990
• Est. Priority Date: 04/27/1984
• Status: Expired due to Fees

• Current Assignee: Quixote Corporation (Trinity Industries Incorporated)
• Original Assignee: Medaphore Incorporated
• Inventors: Ecanow, Bernard
• Primary Examiner(s): Lovering, Richard D.
• Application Number:
  US07/130,550
• Time in Patent Office: 1,036 Days
• Field of Search: 252/312, 264/4.1, 264/4.32, 264/4.7, 428/402.2, 514/78, 514/832, 514/833, 514/911, 514/963, 514/944, 514/959, 514/947, 514/965, 514/975, 128/200.16, 604/892.1, 424/485, 424/486, 424/455, 424/460, 424/484
• US Class Current: 424/485
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/38 Albumins
• CPC Class Codes: A61K 38/39 Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
• CPC Class Codes: A61K 9/0026 Blood substitute; Oxygen transporting formulations; Plasma extender
• CPC Class Codes: A61K 9/1075 Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers A61K9/0026 takes precedence
• CPC Class Codes: A61K 9/5089 Processes
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: Y10T 428/2984 Microcapsule with fluid core [includes liposome]

Abstract

Drug delivery compositions yeild new and unexpected degrees of stabilization, solubilization and delivery of incorporated medicaments, drugs, or other physiologically-active compounds. The compositions enable administration of drugs and other medically useful compounds via a variety of routes. More particularly, a drug delivery system or composition including one or more monomeric or polymerized surface active agents allows for rapid dissolution and smooth liberation of any desired incorporated drug or combinations, and the method of preparing the drug composition. In one embodiment, the physiologically-active compound is encapsulated by a coacervate-derived film, and the finished product is suitable for transmucosal administration. Other formulations of this invention may be administered via inhalation, oral, parenteral and by transdermal and transmucosal routes.

Claims

1. A method of preparing a composition useful as a system to introduce and transport medically useful compositions in the body of mammals;

said composition comprising particles of a coacervate-based matrix having one or more physiologically-active compound incorporated therein and a coacervative-based encapsulating film surrounding each particle;

said method comprising forming a mixture of one or more surface active agents, water and one or more physiologically-active compounds to produce a two phase aqueous coacervate composition containing said compound, and emulsifying the composition to produce an aqueous emulsion of coacervate-based matrix particles containing the physiologically-active compound, said coacervate-based matrix comprising water selected from the group consisting of coacervate phase water, equilibrium phase water, and mixtures thereof, and said physiologically-active compound solubilized therein, said particles having an encapsulating coacervate-based film surrounding the particles.

2. The method of claim 1 further including adding an organic solvent to the mixture to form the two phase coacervate composition.

3. The method of claim 2 wherein the organic solvent comprises N-butyl alcohol or a glyceride.

4. The method of claim 1 wherein the surface active agents comprises a composition of a surface active protein and a surface active phospholipid.

5. A method of preparing a composition containing one or more physiologically-active compounds for oral, inhalation, tissue absorptive or parenteral administration to a mammal comprising emulsifying an aqueous solution of water, a polymerized or polymerizable surface active agent, a coacervating agent and a physicologically-active compound to form an aqueous emulsion of coacervate-based matrix particles containing the physiologically-active compound solubilized therein, and bound in the coacervate matrix within a coacervate-based aqueous film containing the polymerized surface active agent wherein said coacervate matrix comprises water selected from the group consisting of coacervate phase water, equilibrium phase water, and mixtures thereof, and said physiologically-active compound solubilized therein.

6. The method of claim 5 further including emulsifying and microemulsifying the composition to form coacervate particles useful for oral administration having a particle size less than about 800 microns.

7. The method of claim 5 wherein the coacervate particles are microemulsified to less than about 1 micron.

8. The method of claim 5 wherein the surface active agent is a polymerized phospholipid.

9. The method of claim 8 wherein the polymerized phospholipid is polymerized lecithin.

10. The method of claim 8 wherein the phospholipid is selected from the group consisting of lecithin, cephalin, isolecithin, sphingomyelin, phosphalidyl serine, phosphatidic acid, phosphatidyl inositol, phosphatidyl choline, and mixtures thereof.

11. The method of claim 5 wherein the coacervate system includes two surface active agents, at least one of which is a polymer having a molecular weight of 300,000 or less.

12. The method of claim 11 wherein the two surface active agents comprise a phospholipid and a surface active protein.

13. The method of claim 12 wherein the two surface active agents comprise lecithin and polymerized albumin.

14. The method of claim 5 further including drying the composition to form a powder capable of being reconstituted by the addition of a physiologically-acceptable liquid.

15. The method of claim 5 wherein the surface active agent is added in monometric form and further including adding a polymerization initiator to said composition, said polymerization initiator capable of and in an amount sufficient to polymerize the surface active agent during processing of said composition.

16. The method of claim 15 wherein the polymerization initiator is 1-ethyl-3-dimethyl-aminopropylcarbodiimide.

17. The method of claim 5 wherein the physiologically-active compound is a peptide.

18. The method of claim 17 wherein the physiologically-active compound is a polypeptide.

19. The method of claim 5 including admixing with the coacervate composition a glyceride selected from the group consisting of a monoglyceride, a diglyceride, a triglyceride, and mixtures thereof;

said physiologically-active compound being dissolved or dispersed in the glyceride;

said aqueous coacervate-based matrix particles encapsulated in a coacervate-based film encapsulating the glyceride and the physiologically-active compound within the coacervate-based matrix particles, said coacervate-based matrix particles comprising water selected form the group consisting of coacervate phase water, equilibrium phase water, and mixtures thereof, the glyceride, and the physiologically-active compound dissolved or dispersed within the matrix particles.

20. The method of claim 19 wherein the glyceride is a triglyceride having 8 to 18 carbon atoms per each substituted acid chain.

21. A method of introducing a physiologically-active compound into the circulatory system of a mammal comprising having the mammal orally ingest a composition comprising an aqueous coacervate system including water and a surface active agent, said coacervate system including an aqueous emulsion of coacervate-based matrix particles containing the compound solubilized therein;

said aqueous coacervate-based matrix comprising water selected from the group consisting of coacervate phase water, equilibrium phase water, and mixtures thereof, and said physiologically-active compound solubilized therein.

22. The method of claim 21 wherein the surface active agent comprises a protein, polymerized protein, phospholipid, polymerized phospholipid, or mixtures thereof.

23. The method of claim 22 wherein the polymerized protein is polymerized albumin.

24. The method of claim 22 wherein the polymerized phospholipid is a polymer of a compound selected from the group consisting of lecithin, cephalin, isolecithin, sphingomyelin, phosphatidyl serine, phosphatidic acid, phosphatidyl inositol, phosphatidyl choline, and mixtures thereof.

25. The method of claim 24 wherein the polymerized phospholipid is polymerized lecithin.

26. The method of claim 21 further including the step of drying the coacervate to form a powder capable of being reconstituted by the addition of a physiologically-acceptable fluid.

27. A method of introduction a drug into the circulatory system of a mammal comprising having the mammal orally ingest a composition comprising an aqueous emulsion of coacervate-based matrix particles containing water, a surface active agent, and a drug solubilized therein;

said coacervate system including a coacervate-based matrix containing the drug in aqueous solution; and

a coacervate-based film encapsulating the matrix particles, said aqueous coacervate-based matrix particles comprising water selected from the group consisting of coacervate phase water, equilibrium phase water, and mixtures thereof and the drug.

28. The method of claim 27 wherein the drug comprises insulin.

29. The method of claim 27 wherein the drug comprises an atrial peptide.

30. A method of introducing a drug into the circulatory system of a mammal comprising injecting the body of the mammal with a composition comprising an aqueous coacervate composition including water, a surface active agent, and a drug;

said coacervate composition including a coacervate-based matrix containing the drug in aqueous solution or aqueous suspension and a film encapsulating the matrix particles;

said aqueous matrix particles containing water selected from the group consisting of coacervate phase water, equilibrium phase water, and mixtures thereof, and the drug solubilized or dispersed therein.

31. The method of claim 30 wherein the drug comprises an atrial peptide.

32. A method of preparing a composition containing one or more physiologically-active compounds for oral, tissue absorptive, inhalation, or parenteral administration to a mammal comprising mixing an aqueous solution of water, a surface active agent, a coacervating agent and a physiologically-active compound to form a two phase aqueous coacervate composition containing the physiologically-active compound in one or both of the two-phase bound as particles in a coacervate matrix and within a coacervate-based aqueous film containing the surface active agent, said coacervate-based matrix comprising water selected from the group consisting of coacervate phase water, equilibrium phase water, and mixtures thereof and the physiologically-active compound in solution within the matrix water;

separating the particles; and

adding a hydrocolloid to the particles in an amount of 2-20% w/v to form a gel-like surface film surrounding the matrix particles containing the physiologically-active compound.

33. The method of claim 32 further including emulsifying and microemulsifying the composition to form coacervate particles useful for oral administration.

34. The method of claim 32 further including emulsifying and microemulsifying the composition to form coacervate particles useful for oral administration having a particle size less than about 10 microns.

35. The method of claim 32 wherein the coacervate particles are microemulsified to less than about 2 microns.

36. The method of claim 32 wherein the coacervate particles are microemulsified to less than about 1 micron.

37. The method of claim 32 wherein the surface active agent is a polymerized phospholipid.

38. The method of claim 32 further including adding an anti-oxidant to the separated particles.

39. A method of introducing a drug into the circulatory system of a mammal comprising having the mammal orally ingest a composition comprising an aqueous coacervate system including water, a surface active agent, and a drug;

said coacervate system including a coacervate-based matrix containing the drug and a film encapsulating the matrix particles;

said aqueous coacervate-based matrix comprising water selected from the group consisting of coacervate phase water, equilibrium phase water, and mixtures thereof, and the drug in solution within the matrix water;

separating the particles; and

adding a hydrocolloid to the particles in an amount of 2-20% w/v to form a gel-like surface film surrounding the matrix particles containing the drug.

40. The method of claim 39 wherein the surface active agent comprises a protein, polymerized protein, phospholipid, polymerized phospholipid, or mixtures thereof.

41. The method of claim 39 wherein the drug comprises insulin.

42. The method of claim 39 wherein the drug comprises an atrial peptide.

43. A method of preparing a composition useful as a system to introduce and transport medically useful composition in the body of mammals;

said composition comprising an aqueous emulsion of particles of a coacervate-based matrix having one or more physiologically-active compounds incorporated therein;

said coacervate-based matrix comprising water selected from the group consisting of coacervate phase water, equilibrium phase water, and mixtures thereof, said matrix particles including the physiologically-active compound solubilized in the matrix water;

said method comprising forming a mixture of one or more surface active agents, water and one or more physiologically-active compounds to produce a two phase aqueous coacervate composition containing said compounds, and emulsifying the composition under conditions to produce an aqueous emulsion of the coacervate-based matrix particles containing the physiologically-active compound.

44. A method of administering a physiologically-active compound to a mammal comprising topically applying a coacervate composition containing a physiologically-active compound on the skin of a mammal;

said coacervate composition comprising an aqueous emulsion of coacervate-based matrix particles, said matrix particles comprising water, selected from the group consisting of coacervate phase water, equilibrium phase water, and mixtures thereof, said matrix particles including the physiologically-active compound solubilized in the matrix water; and

applying sound waves to the topically applied coacervate composition to drive the coacervate composition into the skin.

45. A method of maintaining tissue or an organ of a mammal viable, outside of the mammal'"'"'s body comprising forming a mixture of one or more surface active agents and water to form a two phase aqueous coacervate composition, and emulsifying the composition to form an aqueous emulsion of coacervate-based matrix particles comprising water selected from the group consisting of coacervate phase water, equilibrium phase water, and mixtures thereof, said matrix particles having solubilized within the matrix water, a compound capable of extending the life of the organ when in contact therewith, and contacting the tissue or organ, outside of the mammal'"'"'s body, with said aqueous emulsion to maintain the visibility of the tissue or organ until said tissue organ is attached to a mammal.